Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2019-01-02 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
上海荣正投资咨询股份有限公司关于公司2019年股票期权激励计划（草案）之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an Independent Financial Advisor Report regarding a 2019 stock option incentive plan (draft) for the company 健帆生物科技集团股份有限公司. It contains detailed analysis and opinions on the stock option plan's compliance with laws and regulations, feasibility, scope of incentive targets, allocation, financial impact, and performance assessment. The document is about a stock option incentive plan and the financial advisor's report on it, not a general annual or quarterly financial report. It is not a simple announcement or certification but a detailed advisory report. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial matters, excluding full annual reports. The document is 14,202 characters long, indicating substantive content rather than a brief announcement. Therefore, the classification is AR with high confidence. FY 2019
2019-01-02 Chinese
独立董事关于第三届董事会第二十八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 28th meeting of the third board of directors of a company. It includes detailed opinions on a 2019 stock option incentive plan, its compliance with laws and regulations, and the nomination of a non-independent director. The content is focused on governance, compliance, and board matters rather than financial results or audit reports. The document length is 1829 characters, which is relatively short and does not contain financial statements or data. It is not an announcement of a report but an opinion related to board decisions and governance. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management.
2019-01-02 Chinese
关于部分理财产品到期赎回的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the progress of redemption of certain financial products (理财产品) that have matured. It details specific financial product purchases, redemption amounts, yields, and risk management measures. The document references prior announcements and shareholder meeting resolutions related to cash management and investment of idle funds. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a transcript, audit report, or management discussion. The document is a regulatory announcement about the status and progress of financial product redemptions and related risk disclosures. It fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-12-27 Chinese
关于部分理财产品到期赎回的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of redemption of certain financial products (理财产品) that have matured. It details amounts, dates, yields, and risk management measures related to cash management and investment products. It references a recent shareholders' meeting resolution approving the use of idle funds for cash management. The document is not a full financial report, earnings release, or management discussion. It is a regulatory announcement about the company's capital management activities and investment product redemptions. It does not contain comprehensive financial statements or detailed financial analysis. The document length is about 5609 characters, which is relatively short and focused on a specific update. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to updates on company financing activities and capital usage.
2018-12-26 Chinese
关于部分高级管理人员减持计划时间过半的进展公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress of a shareholding reduction plan by a senior management member (Vice General Manager Zeng Kai) of the company. It details the number of shares reduced, the method of reduction, and compliance with relevant securities laws and regulations. The document does not contain financial statements or performance data, nor is it a report or presentation. It is a disclosure about insider share transactions by a company executive, which fits the definition of Director's Dealing (DIRS). The document length is short and focused solely on this insider transaction update, confirming it is not a full report or earnings release.
2018-12-26 Chinese
关于部分理财产品到期赎回的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the progress of redemption of certain financial products (理财产品) that have matured. It details specific financial product purchases, redemption amounts, yields, risks, and measures taken. It references a recent shareholders meeting approving the use of idle funds for cash management. The document is an update on financing activities related to cash management and investment products, not a full financial report or earnings release. It is not an annual or interim report, nor a regulatory filing or certification. The content fits best with a Capital/Financing Update (CAP) as it provides detailed information on the company's cash management and investment product redemptions and related financial activities.
2018-12-25 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.